Insider Trading Alert - EW, SLAB And LCI Traded By Insiders - TheStreet

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 29, 2014, 60 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,000.00 to $206,654,400.00.

Highlighted Stocks Traded by Insiders:

Edwards Lifesciences (EW) - FREE Research Report

Mcneil Barbara J, who is Director at Edwards Lifesciences, sold 1,000 shares at $117.94 on Oct. 29, 2014. Following this transaction, the Director owned 52,737 shares meaning that the stake was reduced by 1.86% with the 1,000-share transaction.

The shares most recently traded at $119.73, up $1.79, or 1.5% since the insider transaction. Historical insider transactions for Edwards Lifesciences go as follows:

  • 4-Week # shares sold: 6,000
  • 12-Week # shares sold: 6,000
  • 24-Week # shares sold: 28,550

The average volume for Edwards Lifesciences has been 890,200 shares per day over the past 30 days. Edwards Lifesciences has a market cap of $12.5 billion and is part of the health care sector and health services industry. Shares are up 82.48% year-to-date as of the close of trading on Wednesday.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company has a P/E ratio of 33.0. Currently, there are 11 analysts who rate Edwards Lifesciences a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EW - FREE

TheStreet Quant Ratings

rates Edwards Lifesciences as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Edwards Lifesciences Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Silicon Laboratories (SLAB) - FREE Research Report

Sooch Navdeep S, who is Director at Silicon Laboratories, sold 15,300 shares at $45.21 on Oct. 29, 2014. Following this transaction, the Director owned 720,327 shares meaning that the stake was reduced by 2.08% with the 15,300-share transaction.

The shares most recently traded at $44.07, down $1.14, or 2.6% since the insider transaction. Historical insider transactions for Silicon Laboratories go as follows:

  • 4-Week # shares bought: 1,400
  • 4-Week # shares sold: 1,484
  • 12-Week # shares bought: 1,400
  • 12-Week # shares sold: 12,700
  • 24-Week # shares bought: 1,400
  • 24-Week # shares sold: 17,900

The average volume for Silicon Laboratories has been 411,900 shares per day over the past 30 days. Silicon Laboratories has a market cap of $1.9 billion and is part of the technology sector and electronics industry. Shares are up 4.36% year-to-date as of the close of trading on Wednesday.

Silicon Laboratories Inc., a fabless semiconductor company, designs and develops analog-intensive, mixed-signal integrated circuits (ICs). The company has a P/E ratio of 52.0. Currently, there are 7 analysts who rate Silicon Laboratories a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SLAB - FREE

TheStreet Quant Ratings

rates Silicon Laboratories as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full

Silicon Laboratories Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Lannett (LCI) - FREE Research Report

Farber David, who is 10% Owner at Lannett, sold 7,500 shares at $50.00 on Oct. 29, 2014. Following this transaction, the 10% Owner owned 58,370 shares meaning that the stake was reduced by 11.39% with the 7,500-share transaction.

The shares most recently traded at $54.45, up $4.45, or 8.17% since the insider transaction. Historical insider transactions for Lannett go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 30,000
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 63,500

The average volume for Lannett has been 687,000 shares per day over the past 30 days. Lannett has a market cap of $1.9 billion and is part of the health care sector and drugs industry. Shares are up 58.58% year-to-date as of the close of trading on Wednesday.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas. The company has a P/E ratio of 32.8. Currently, there are 3 analysts who rate Lannett a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LCI - FREE

TheStreet Quant Ratings

rates Lannett as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Lannett Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by

Zacks Investment Research

null